Authors' contribution: Dr. Jing SW performed all the experiments and prepared the article (contribution: 30%), Dr. Wang YD designed and directed the project and revised the article (contribution: 40%), all other co-authors participated in the study in patients recruitment, data collection, data analysis, and article preparation (jointly contributed 30%).
1442-2050/asset/olbannerleft.gif?v=1&s=ef9f78d0ca869ea23b87ef11f2e9f8520470248e)
1442-2050/asset/olbannercenter.gif?v=1&s=249086efa64e40596c941af23c854ef64473dad6)
Original article
You have free access to this content
Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation
Article first published online: 17 FEB 2012
DOI: 10.1111/j.1442-2050.2011.01321.x
© 2012 Copyright the Authors. Journal compilation © 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
Additional Information
How to Cite
Jing, S.-w., Wang, Y.-d., Chen, L.-Q., Sang, M.-x., Zheng, M.-m., Sun, G.-g., Liu, Q., Cheng, Y.-j. and Yang, C.-r. (2013), Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation. Diseases of the Esophagus, 26: 75–83. doi: 10.1111/j.1442-2050.2011.01321.x
Publication History
- Issue published online: 8 JAN 2013
- Article first published online: 17 FEB 2012
References
- 1. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625–34.
- 2, . Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230–7.
- 3, , et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363–75.
- 4, , . Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009; 280: 145–53.
- 5, , , . Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435–47.
- 6, , , , , . Gene expression profiling of fixed tissues identified HIF-1{alpha}, VEGF, and MMP-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 2011; 17: 5463–72.
- 7, , , . Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol 2011; 38: 305–12.
- 8, , , , . Interference of HIF-1 alpha by RNA reduces the expression of matrix metalloproteinase-2 in human cervical carcinoma HeLa cells. Ai Zheng 2008; 27: 600–5.
- 9, , et al. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Cancer Lett 2009; 278: 210–19.
- 10, , . Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425–37.
- 11, . Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005; 338: 617–26.
- 12, , . RNA interference and its possible use in cancer therapy. Bull Cancer 2004; 91: 15–18.
- 13, , et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–5.
- 14, , et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem 2010; 285: 6658–69.
- 15, . The expression and clinical significance of HIF-1α, COX-2 and E-cadherin in patients with lung adenocarcinoma. Zhongguo Fei Ai Za Zhi 2011; 14: 219–26.
- 16, , . Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415–28.
- 17, , et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003; 163: 1437–47.
- 18. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38–47.
- 19, , , , . HIF-1α and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res 2011; 167: 41–8.